T Man Pharmaceutical PCL vs Zhejiang Huahai Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

T Man Pharmaceutical PCL (TMAN.BK)

Q3 202622 Jul – 8 Oct 2026

▲3

TMAN bets on longevity, Propoliz exports and hospital push for 4bn baht

Longevity New S-Curve and 4bn baht target TMAN set a goal of 4 billion baht revenue in 3-5 years (from 2.5 billion in 2025), adding a longevity supplement business with 15-20 new products a year and a new own brand. This gives investors a bigger growth story, which supports the share price.
It is the main new strategic plan that reframes TMAN's growth outlook.
Propoliz pushed to regional and global brand TMAN is expanding Propoliz beyond 7 countries to 10+, with South Korea and Indonesia distributor deals and first Korea shipment in October, plus a celebrity 'Friends of Propoliz' campaign. More export markets and marketing mean more sales, lifting profit expectations.
Export expansion and marketing are concrete new demand drivers for the key brand.
Hospital channel and OEM growth TMAN plans to raise hospital channel revenue share to 15-20% from 10%, and its OEM contract manufacturing has grown over 100%, recently adding a major customer. Higher-margin channels and bigger OEM orders support revenue and profit recovery.
It shows where near-term growth is coming from beyond the pharmacy slump.
Weak first-half profit but recovery expected First-half net profit fell 7.2% to 212 million baht on higher marketing and tax costs, even as revenue rose 8.2%. Management and brokers still expect a strong second-half recovery, so the weak result is a real counterweight but seen as temporary.
It is the key negative fact readers must weigh against the growth plans.

August 202622 Jul – 8 Oct 2026

▲3

TMAN bets on longevity, Propoliz exports and hospital push for 4bn baht

Longevity New S-Curve and 4bn baht target TMAN set a goal of 4 billion baht revenue in 3-5 years (from 2.5 billion in 2025), adding a longevity supplement business with 15-20 new products a year and a new own brand. This gives investors a bigger growth story, which supports the share price.
It is the main new strategic plan that reframes TMAN's growth outlook.
Propoliz pushed to regional and global brand TMAN is expanding Propoliz beyond 7 countries to 10+, with South Korea and Indonesia distributor deals and first Korea shipment in October, plus a celebrity 'Friends of Propoliz' campaign. More export markets and marketing mean more sales, lifting profit expectations.
Export expansion and marketing are concrete new demand drivers for the key brand.
Hospital channel and OEM growth TMAN plans to raise hospital channel revenue share to 15-20% from 10%, and its OEM contract manufacturing has grown over 100%, recently adding a major customer. Higher-margin channels and bigger OEM orders support revenue and profit recovery.
It shows where near-term growth is coming from beyond the pharmacy slump.
Weak first-half profit but recovery expected First-half net profit fell 7.2% to 212 million baht on higher marketing and tax costs, even as revenue rose 8.2%. Management and brokers still expect a strong second-half recovery, so the weak result is a real counterweight but seen as temporary.
It is the key negative fact readers must weigh against the growth plans.

Latest22 Jul – 8 Oct 2026

▲3

TMAN bets on longevity, Propoliz exports and hospital push for 4bn baht

Longevity New S-Curve and 4bn baht target TMAN set a goal of 4 billion baht revenue in 3-5 years (from 2.5 billion in 2025), adding a longevity supplement business with 15-20 new products a year and a new own brand. This gives investors a bigger growth story, which supports the share price.
It is the main new strategic plan that reframes TMAN's growth outlook.
Propoliz pushed to regional and global brand TMAN is expanding Propoliz beyond 7 countries to 10+, with South Korea and Indonesia distributor deals and first Korea shipment in October, plus a celebrity 'Friends of Propoliz' campaign. More export markets and marketing mean more sales, lifting profit expectations.
Export expansion and marketing are concrete new demand drivers for the key brand.
Hospital channel and OEM growth TMAN plans to raise hospital channel revenue share to 15-20% from 10%, and its OEM contract manufacturing has grown over 100%, recently adding a major customer. Higher-margin channels and bigger OEM orders support revenue and profit recovery.
It shows where near-term growth is coming from beyond the pharmacy slump.
Weak first-half profit but recovery expected First-half net profit fell 7.2% to 212 million baht on higher marketing and tax costs, even as revenue rose 8.2%. Management and brokers still expect a strong second-half recovery, so the weak result is a real counterweight but seen as temporary.
It is the key negative fact readers must weigh against the growth plans.

Zhejiang Huahai Pharmaceutical Co Ltd (600521.CG)

Q3 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

August 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

Latest24 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.